The effects of weight on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules

被引：0
|
作者：
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
机构：
来源：
MOVEMENT DISORDERS | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
410
引用
收藏
页码：S146 / S147
页数：2
相关论文
共 50 条
  • [21] Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease
    Tetrud, James
    Nausieda, Paul
    Kreitzman, David
    Liang, Grace S.
    Nieves, Anette
    Duker, Andrew P.
    Hauser, Robert A.
    Farbman, Eric S.
    Ellenbogen, Aaron
    Hsu, Ann
    Kell, Sherron
    Khanna, Sarita
    Rubens, Robert
    Gupta, Suneel
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 373 : 116 - 123
  • [22] Efficacy of IPX066, extended-release levodopa-carbidopa in patients with advanced Parkinson's disease: Responder analyses
    Gupta, Suneel
    Khanna, Sarita
    Rustay, Nathan
    Rubens, Robert
    Kell, Sherron
    MOVEMENT DISORDERS, 2017, 32 : S36 - S36
  • [23] Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
    Hauser, Robert A.
    Hsu, Ann
    Kell, Sherron
    Espay, Alberto J.
    Sethi, Kapil
    Stacy, Mark
    Ondo, William
    O'Connell, Martin
    Gupta, Suneel
    LANCET NEUROLOGY, 2013, 12 (04): : 346 - 356
  • [24] Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease
    Pahwa, Rajesh
    Lyons, Kelly E.
    Hauser, Robert A.
    Fahn, Stanley
    Jankovic, Joseph
    Pourcher, Emmanuelle
    Hsu, Ann
    O'Connell, Martin
    Kell, Sherron
    Gupta, Suneel
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (02) : 142 - 148
  • [25] Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
    LeWitt, Peter A.
    Metman, Leo Verhagen
    Rubens, Robert
    Khanna, Sarita
    Kell, Sherron
    Gupta, Suneel
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (02) : 47 - 55
  • [26] PHARMACODYNAMICS OF IPX066, AN EXTENDED-RELEASE CAPSULE FORMULATION OF CARBIDOPA-LEVODOPA (CD-LD), IN PATIENTS WITH EARLY PARKINSON'S DISEASE: A DISEASE PROGRESSION MODEL
    Mao, Z.
    Hsu, A.
    Gupta, S.
    Modi, N. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S81 - S81
  • [27] Safety analysis by higher and lower total daily dose of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease
    Hinson, V. K.
    Stover, N.
    Agarwal, P.
    Khanna, S.
    Kell, S.
    MOVEMENT DISORDERS, 2015, 30 : S90 - S91
  • [28] Extended-release carbidopa- levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson's disease
    Gupta, S.
    Khanna, S.
    Kell, S.
    Rubens, R.
    MOVEMENT DISORDERS, 2016, 31 : S670 - S670
  • [29] Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
    Morgan, John C.
    Dhall, Rohit
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    PARKINSONS DISEASE, 2018, 2018
  • [30] Extended-release carbidopa-levodopa in Parkinson's disease
    Rascol, Olivier
    LANCET NEUROLOGY, 2013, 12 (04): : 325 - 326
12345